<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="acer70041" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alcohol Clin Exp Res (Hoboken)</journal-id><journal-id journal-id-type="iso-abbrev">Alcohol Clin Exp Res (Hoboken)</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2993-7175</journal-id><journal-id journal-id-type="publisher-id">ACER</journal-id><journal-title-group><journal-title>Alcohol, Clinical &#x00026; Experimental Research</journal-title></journal-title-group><issn pub-type="epub">2993-7175</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40123107</article-id><article-id pub-id-type="pmc">PMC12098802</article-id>
<article-id pub-id-type="doi">10.1111/acer.70041</article-id><article-id pub-id-type="publisher-id">ACER70041</article-id><article-id pub-id-type="other">ACER-24-6318.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Behavior, Treatment and Prevention</subject></subj-group></article-categories><title-group><article-title>Blood phosphatidylethanol measurements indicate <styled-content style="fixed-case" toggle="no">GLP</styled-content>&#x02010;1 receptor stimulation causes delayed decreases in alcohol consumption</article-title><alt-title alt-title-type="right-running-head">PEth and GLP&#x02010;1 receptor agonists</alt-title><alt-title alt-title-type="left-running-head">Jensen et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="acer70041-cr-0001" contrib-type="author"><name><surname>Jensen</surname><given-names>Mathias E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2555-4785</contrib-id><xref rid="acer70041-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acer70041-cr-0002" contrib-type="author"><name><surname>Klausen</surname><given-names>Mette K.</given-names></name><xref rid="acer70041-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="acer70041-cr-0003" contrib-type="author"><name><surname>Bergmann</surname><given-names>Marianne L.</given-names></name><xref rid="acer70041-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="acer70041-cr-0004" contrib-type="author"><name><surname>Knudsen</surname><given-names>Gitte M.</given-names></name><xref rid="acer70041-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="acer70041-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="acer70041-cr-0005" contrib-type="author"><name><surname>Vilsb&#x000f8;ll</surname><given-names>Tina</given-names></name><xref rid="acer70041-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="acer70041-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="acer70041-cr-0006" contrib-type="author"><name><surname>Stove</surname><given-names>Christophe</given-names></name><xref rid="acer70041-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="acer70041-cr-0007" contrib-type="author" corresp="yes"><name><surname>Fink&#x02010;Jensen</surname><given-names>Anders</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7143-1236</contrib-id><xref rid="acer70041-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="acer70041-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>anders.fink-jensen@regionh.dk</email></address></contrib></contrib-group><aff id="acer70041-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Psychiatric Centre Copenhagen, Frederiksberg</named-content>
<institution>University of Copenhagen</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff id="acer70041-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Biochemistry and Immunology</named-content>
<institution>University Hospital of Southern Denmark</institution>
<city>Vejle</city>
<country country="DK">Denmark</country>
</aff><aff id="acer70041-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Neurobiology Research Unit</named-content>
<institution>Copenhagen University Hospital Rigshospitalet</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff id="acer70041-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Medicine, Faculty of Health and Medical Sciences</named-content>
<institution>University of Copenhagen</institution>
<city>Copenhagen</city>
<country country="DK">Denmark</country>
</aff><aff id="acer70041-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Clinical Research, Steno Diabetes Center Copenhagen</named-content>
<institution>University of Copenhagen</institution>
<city>Herlev</city>
<country country="DK">Denmark</country>
</aff><aff id="acer70041-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences</named-content>
<institution>Ghent University</institution>
<city>Ghent</city>
<country country="BE">Belgium</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Anders Fink&#x02010;Jensen, Psychiatric Centre Copenhagen, Frederiksberg, University of Copenhagen, Copenhagen, Denmark.<break/>
Email: <email>anders.fink-jensen@regionh.dk</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>49</volume><issue seq="210">5</issue><issue-id pub-id-type="doi">10.1111/acer.v49.5</issue-id><fpage>1161</fpage><lpage>1165</lpage><history>
<date date-type="received"><day>20</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>08</day><month>3</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 by the Research Society on Alcohol--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). Alcohol, Clinical and Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcohol.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:ACER-49-1161.pdf"/><abstract><title>Abstract</title><sec id="acer70041-sec-0001"><title>Background</title><p>The investigation of glucagon&#x02010;like peptide 1 (GLP&#x02010;1) receptor agonists (GLP&#x02010;1RA) as a potential treatment for individuals with alcohol use disorder (AUD) and obesity is currently underway. In this secondary analysis of a randomized placebo&#x02010;controlled trial, we included AUD patients with comorbid obesity and assessed the effect of the GLP&#x02010;1RA exenatide versus placebo on alcohol consumption as measured by the alcohol biomarker phosphatidylethanol (PEth).</p></sec><sec id="acer70041-sec-0002"><title>Methods</title><p>Thirty AUD patients (9 females, 21 males), with an average age of 53&#x02009;years and a body mass index (BMI) of at least 30&#x02009;kg/m<sup>2</sup>, were included in this secondary analysis. Blood samples for PEth were collected at baseline and at weeks 4, 12, 20, and 26. The effect of time and treatment on PEth levels was analyzed using a baseline&#x02010;adjusted linear mixed model.</p></sec><sec id="acer70041-sec-0003"><title>Results</title><p>A significant interaction between time and treatment was observed at Week 26, with PEth levels reduced by &#x02212;0.9&#x02009;<italic toggle="no">&#x003bc;</italic>mol/L in the exenatide group compared to placebo (95% CI [&#x02212;1.6 to &#x02212;0.1], <italic toggle="no">p</italic>&#x02009;=&#x02009;0.03). However, the difference in PEth blood levels between the exenatide and placebo groups was not significant at earlier time points.</p></sec><sec id="acer70041-sec-0004"><title>Conclusion</title><p>This secondary analysis indicates that exenatide has a delayed yet significant impact on alcohol consumption in individuals with AUD and obesity, as assessed by PEth levels. These findings warrant further investigation, which is currently underway (NCT05895643).</p></sec></abstract><abstract abstract-type="graphical"><p>Glucagon&#x02010;like peptide 1 receptor agonists (GLP&#x02010;1RAs) are effective for treating obesity (BMI &#x02265;30) and are being investigated as a novel treatment for alcohol use disorder (AUD). This secondary analysis of a randomized clinical trial evaluated the effect of exenatide versus placebo on alcohol consumption using phosphatidylethanol (PEth) in 30 AUD patients with obesity. PEth levels were measured at baseline and weeks 4, 12, 20, and 26. Exenatide significantly reduced PEth at Week 26 but not at earlier time points.<boxed-text position="anchor" content-type="graphic" id="acer70041-blkfxd-0001"><graphic xlink:href="ACER-49-1161-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="acer70041-kwd-0001">alcohol biomarkers</kwd><kwd id="acer70041-kwd-0002">alcohol use disorder</kwd><kwd id="acer70041-kwd-0003">GLP&#x02010;1 receptor agonist</kwd><kwd id="acer70041-kwd-0004">PEth</kwd><kwd id="acer70041-kwd-0005">phosphatidylethanol</kwd></kwd-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="5"/><word-count count="3500"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:22.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ACER70041-cit-2001">
<string-name>
<surname>Jensen</surname>, <given-names>M.E.</given-names>
</string-name>, <string-name>
<surname>Klausen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>, <given-names>M.L.</given-names>
</string-name>, <string-name>
<surname>Knudsen</surname>, <given-names>G.M.</given-names>
</string-name>, <string-name>
<surname>Vilsb&#x000f8;ll</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Stove</surname>, <given-names>C.</given-names>
</string-name> et al. (<year>2025</year>) <article-title>Blood phosphatidylethanol measurements indicate <styled-content style="fixed-case" toggle="no">GLP</styled-content>&#x02010;1 receptor stimulation causes delayed decreases in alcohol consumption</article-title>. <source>Alcohol: Clinical and Experimental Research</source>, <volume>49</volume>, <fpage>1161</fpage>&#x02013;<lpage>1165</lpage>. Available from: <pub-id pub-id-type="doi">10.1111/acer.70041</pub-id>
</mixed-citation>
</p></notes></front><body id="acer70041-body-0001"><sec id="acer70041-sec-0005"><title>INTRODUCTION</title><p>Alcohol use disorder (AUD) is one of the leading causes of disability and death worldwide (Carvalho et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0004" ref-type="bibr">2019</xref>). It is a difficult&#x02010;to&#x02010;treat neuropsychiatric disease characterized by a loss of control over drinking despite the awareness of negative consequences and the emergence of a negative affective state when abstaining from intoxication (Volkow et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0025" ref-type="bibr">2016</xref>). Current FDA&#x02010;approved medications (disulfiram, naltrexone, and acamprosate) are modest in efficacy (Kranzler &#x00026; Soyka,&#x000a0;<xref rid="acer70041-bib-0015" ref-type="bibr">2018</xref>); thus, better treatment options are urgently needed.</p><p>Emerging evidence indicates that appetite&#x02010;regulating peptides modulate the brain's reward system, potentially providing a therapeutic approach to addiction treatment. Notably, glucagon&#x02010;like peptide 1 receptor agonists (GLP&#x02010;1RAs) have garnered attention for their potential application in treating AUD (Leggio et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0016" ref-type="bibr">2023</xref>). In rodents and nonhuman primates, GLP&#x02010;1RAs, such as exenatide and semaglutide, have demonstrated efficacy in attenuating addiction&#x02010;related effects of alcohol, central stimulants, and nicotine (Egecioglu et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0005" ref-type="bibr">2013</xref>; Fink&#x02010;Jensen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0007" ref-type="bibr">2024</xref>; Fortin &#x00026; Roitman,&#x000a0;<xref rid="acer70041-bib-0008" ref-type="bibr">2017</xref>; Graham et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0009" ref-type="bibr">2013</xref>; Reddy et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0019" ref-type="bibr">2016</xref>; S&#x000f8;rensen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0022" ref-type="bibr">2015</xref>; Thomsen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0023" ref-type="bibr">2017</xref>; Tuesta et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0024" ref-type="bibr">2017</xref>). These findings are corroborated by several lines of evidence from human studies, including anecdotal reports of reduced alcohol consumption in individuals with obesity for whom GLP&#x02010;1RAs have been prescribed (Quddos et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0018" ref-type="bibr">2023</xref>); case series reporting decreased symptoms of AUD (Richards et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0020" ref-type="bibr">2023</xref>) after GLP&#x02010;1RA treatment; register&#x02010;based data showing that GLP&#x02010;1RAs were associated with lower incidences of alcohol&#x02010;related events (Wium&#x02010;Andersen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0030" ref-type="bibr">2022</xref>); and real&#x02010;world population data showing that the GLP&#x02010;1RA semaglutide was associated with significantly lower risks of incidence and recurrence of AUD among individuals with obesity or type 2 diabetes (Wang et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0029" ref-type="bibr">2024</xref>). Substantiating these various lines of evidence, we recently showed that the GLP&#x02010;1RA exenatide significantly reduced alcohol cue&#x02010;induced brain activation in AUD patients (Klausen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0013" ref-type="bibr">2022</xref>). However, the number of heavy drinking days and total alcohol consumption were only reduced in those with comorbid obesity, that is, those who had a body mass index (BMI) &#x02265;30&#x02009;kg/m<sup>2</sup> (Klausen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0013" ref-type="bibr">2022</xref>).</p><p>In this study, we conducted a secondary analysis of the exenatide trial data, including only the AUD patients with obesity, to evaluate exenatide's effects on alcohol consumption, as measured by an objective alcohol biomarker, phosphatidylethanol (PEth) (Luginbuhl et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0017" ref-type="bibr">2022</xref>).</p></sec><sec sec-type="materials-and-methods" id="acer70041-sec-0006"><title>MATERIALS AND METHODS</title><p>In the primary trial involving 127 patients, the exenatide group showed a significant reduction in BMI of &#x02212;1.0 (95% CI [&#x02212;1.6 to &#x02212;0.3], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.006) and a nonsignificant decrease in body weight of &#x02212;2.4&#x02009;kg (95% CI [&#x02212;5.0 to 0.2], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.07) compared to placebo. Both groups demonstrated a substantial reduction in alcohol consumption from baseline to Week 26, but the differences between treatments were not statistically significant: a 6.0 percentage point difference in heavy drinking days (95% CI [&#x02212;7.4 to 19.4], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.40), a reduction of &#x02212;42.0&#x02009;g in total alcohol consumption (95% CI [&#x02212;507.7 to 423.7], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.90), and a decrease of &#x02212;0.13&#x02009;<italic toggle="yes">&#x003bc;</italic>mol/L in PEth levels (95% CI [&#x02212;0.7 to 0.4], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.64) (Klausen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0013" ref-type="bibr">2022</xref>).</p><p>In the present secondary analysis, we included 30 AUD patients, 9 female/21 males, with a mean age of 53&#x02009;years, who also met the criteria for obesity, that is, had a BMI &#x02265;30&#x02009;kg/m<sup>2</sup>. At baseline and at weeks 4, 12, 20, and 26 follow&#x02010;up, alcohol consumption was quantified by self&#x02010;reports using the gold standard Timeline Followback Method going 30&#x02009;days back. Moreover, blood samples from nonfasting study participants were analyzed for blood levels of PEth. Blood for PEth analyses was collected in a Vacuette K2 EDTA 2&#x02010;mL tube and immediately stored at &#x02212;20&#x000b0;C/&#x02212;4&#x000b0;F and afterward transferred to a &#x02212;80&#x000b0;C/&#x02212;112&#x000b0;F freezer, where it was kept for a maximum of 3&#x02009;years before being analyzed. Further details of the study methods, including the PEth analysis, are contained in the primary publication (Klausen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0013" ref-type="bibr">2022</xref>).</p><sec id="acer70041-sec-0007"><title>Data analysis</title><p>The effect of time and treatment on PEth levels was analyzed using a linear mixed model adjusted for baseline, which further assumed an unstructured covariance pattern to account for repeated measurements on the same participants. Age and sex were added to the model as covariates to assess their potential influence. Correlations between self&#x02010;reported alcohol consumption over the past 30&#x02009;days and PEth levels were calculated using Spearman's rank&#x02010;order correlation coefficient and Bonferroni&#x02010;corrected for multiple testing. Missing data were handled by using a complete information maximum likelihood method. The level of statistical significance was 5% and 95% confidence intervals. We used the R software version 2023.03.1&#x02009;+&#x02009;446, LMMstar package for the linear mixed model analysis, and ggplot2 package for plots.</p></sec></sec><sec sec-type="results" id="acer70041-sec-0008"><title>RESULTS</title><sec id="acer70041-sec-0009"><title>Characteristics of the participants</title><p>At baseline, the exenatide group had a significantly higher AUDIT score. In line with this, although not statistically significant (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.08), they also reported larger percentages of heavy drinking days and total alcohol intake (grams of total alcohol consumption) (Table&#x000a0;<xref rid="acer70041-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="acer70041-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Baseline characteristics of the participant's BMI, Body Mass Index, AUDIT, Alcohol Use Identification Test, percentage of heavy drinking days, and the number of days within the past month where the participant reported having drinking &#x0003e; five/ &#x0003e; four drinks (men/women).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Exenatide (means &#x000b1; SD)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Placebo (means &#x000b1; SD)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;Value<xref rid="acer70041-note-0002" ref-type="table-fn">*</xref>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">No.</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="left" valign="top" rowspan="1" colspan="1">54.9&#x02009;&#x000b1;&#x02009;9.7</td><td align="left" valign="top" rowspan="1" colspan="1">51.9&#x02009;&#x000b1;&#x02009;9.8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female/Male</td><td align="left" valign="top" rowspan="1" colspan="1">5 / 10</td><td align="left" valign="top" rowspan="1" colspan="1">4 / 11</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight, kg</td><td align="left" valign="top" rowspan="1" colspan="1">105.9&#x02009;&#x000b1;&#x02009;13.4</td><td align="left" valign="top" rowspan="1" colspan="1">99.7&#x02009;&#x000b1;&#x02009;13.7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">34.1&#x02009;&#x000b1;&#x02009;3.8</td><td align="left" valign="top" rowspan="1" colspan="1">33.2&#x02009;&#x000b1;&#x02009;2.8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DSM&#x02010;5 AUD criteria</td><td align="left" valign="top" rowspan="1" colspan="1">7.3&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" valign="top" rowspan="1" colspan="1">7.1&#x02009;&#x000b1;&#x02009;2.3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUDIT score</td><td align="left" valign="top" rowspan="1" colspan="1">26.7&#x02009;&#x000b1;&#x02009;4.3</td><td align="left" valign="top" rowspan="1" colspan="1">22.3&#x02009;&#x000b1;&#x02009;3.7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Heavy drinking days, %</td><td align="left" valign="top" rowspan="1" colspan="1">63.8&#x02009;&#x000b1;&#x02009;25.6</td><td align="left" valign="top" rowspan="1" colspan="1">50.9&#x02009;&#x000b1;&#x02009;27.5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol, grams</td><td align="left" valign="top" rowspan="1" colspan="1">3097.3&#x02009;&#x000b1;&#x02009;1931.5</td><td align="left" valign="top" rowspan="1" colspan="1">1935.8&#x02009;&#x000b1;&#x02009;1509.0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood PEth, <italic toggle="yes">&#x003bc;</italic>mol/L</td><td align="left" valign="top" rowspan="1" colspan="1">1.1&#x02009;&#x000b1;&#x02009;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.2&#x02009;&#x000b1;&#x02009;1.7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.9</td></tr></tbody></table><table-wrap-foot id="acer70041-ntgp-0001"><fn id="acer70041-note-0001"><p>Abbreviation: PEth, phosphatidylethanol.</p></fn><fn id="acer70041-note-0002"><label>*</label><p>
<italic toggle="yes">p</italic> values determined by independent <italic toggle="yes">t</italic> test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="acer70041-sec-0010"><title>Effects of exenatide on blood <styled-content style="fixed-case" toggle="no">PEth</styled-content> levels across study weeks</title><p>There was a significant interaction between time and treatment at week 26, where exenatide significantly reduced PEth levels by &#x02212;0.9&#x02009;<italic toggle="yes">&#x003bc;</italic>mol/L compared to placebo (95% CI [&#x02212;1.6 to &#x02212;0.1], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.03). However, differences in PEth blood levels between the exenatide and placebo groups were not significant at earlier time points: at Week 4, the estimated difference was 0.1&#x02009;<italic toggle="yes">&#x003bc;</italic>mol/L (95% CI [&#x02212;1.2 to 1.0], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.9); at Week 12, the difference was &#x02212;0.3&#x02009;<italic toggle="yes">&#x003bc;</italic>mol/L (95% CI [&#x02212;1.0 to 0.3], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.3); and at Week 20, the difference was &#x02212;0.3&#x02009;<italic toggle="yes">&#x003bc;</italic>mol/L (95% CI [&#x02212;0.9 to 0.4], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.4). Including age (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.3) or gender (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.7) as covariates in the linear mixed model did not alter the primary conclusion (Figure&#x000a0;<xref rid="acer70041-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="acer70041-fig-0001"><label>FIGURE 1</label><caption><p>The effect of time and treatment (exenatide vs. placebo) on PEth levels in individuals with AUD and obesity. Data are presented as means (SEM). PEth, phosphatidylethanol.</p></caption><graphic xlink:href="ACER-49-1161-g001" position="anchor" id="jats-graphic-3"/></fig><p>PEth levels and self&#x02010;reports of alcohol consumption were significantly correlated at all assessment time points except Week 12: baseline, <italic toggle="yes">&#x003c1;</italic>(30)&#x02009;=&#x02009;0.6, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01, Week 4, <italic toggle="yes">&#x003c1;</italic>(27)&#x02009;=&#x02009;0.6, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02; Week 12, <italic toggle="yes">&#x003c1;</italic>(21)&#x02009;=&#x02009;0.4, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.13; Week 20, <italic toggle="yes">&#x003c1;</italic>(14)&#x02009;=&#x02009;0.8, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01; and Week 26, <italic toggle="yes">&#x003c1;</italic>(18)&#x02009;=&#x02009;0.7, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01. See Figure&#x000a0;<xref rid="acer70041-fig-0002" ref-type="fig">2</xref>.</p><fig position="float" fig-type="FIGURE" id="acer70041-fig-0002"><label>FIGURE 2</label><caption><p>Blood levels of PEth versus percentage of heavy drinking days the past 30&#x02009;days, assessed at baseline, Week 4, Week 12, Week 20, and Week 26 (end of the trial). PEth levels and self&#x02010;reports of alcohol consumption were significantly correlated at all assessment time points except Week 12: Baseline, <italic toggle="yes">&#x003c1;</italic>(30)&#x02009;=&#x02009;0.6, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01, Week 4, <italic toggle="yes">&#x003c1;</italic>(27)&#x02009;=&#x02009;0.6, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02, Week 12, <italic toggle="yes">&#x003c1;</italic>(21)&#x02009;=&#x02009;0.4, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.13, Week 20, <italic toggle="yes">&#x003c1;</italic>(14)&#x02009;=&#x02009;0.8, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01, and Week 26, <italic toggle="yes">&#x003c1;</italic>(18)&#x02009;=&#x02009;0.7, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.01. Dashed lines represent regression lines with confidence bands (gray). PEth, phosphatidylethanol.</p></caption><graphic xlink:href="ACER-49-1161-g003" position="anchor" id="jats-graphic-5"/></fig><p>To ensure the robustness of our findings, we conducted a sensitivity analysis including only participants who completed the study through Week 26 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;9 in each group i.e., per protocol). The results remained consistent, with exenatide significantly reducing PEth levels at Week 26 by &#x02212;1.0&#x02009;<italic toggle="yes">&#x003bc;</italic>mol/L compared to baseline (95% CI [&#x02212;1.8 to &#x02212;0.3], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.009), demonstrating that participant dropouts did not impact the results.</p></sec></sec><sec sec-type="discussion" id="acer70041-sec-0011"><title>DISCUSSION</title><p>In this secondary analysis, we evaluated the effects of exenatide compared to placebo on alcohol consumption in AUD patients with comorbid obesity, as measured by the alcohol biomarker PEth. Our results show that blood levels of PEth were significantly reduced in the exenatide group compared to the placebo group at Week 26, but not earlier. Importantly, a delayed effect of exenatide on alcohol consumption was also observed in the primary trial analysis (Klausen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0013" ref-type="bibr">2022</xref>). The relation between self&#x02010;reported alcohol consumption and PEth is in line with previous research (Kechagias et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0012" ref-type="bibr">2015</xref>; Richards et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0021" ref-type="bibr">2021</xref>; Walther et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0028" ref-type="bibr">2015</xref>). Several factors may explain the delayed effect of exenatide. The extended&#x02010;release form of exenatide used in this trial (Bydureon&#x000ae;, once&#x02010;weekly injections) reaches a steady state and achieves its full therapeutic effect on glycemic control within approximately 7&#x02009;weeks (Fineman et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0006" ref-type="bibr">2011</xref>). Thus, the protracted time to steady state may contribute to the delayed impact on PEth observed here. Additionally, the complex neurobiological mechanisms underlying rigid, maladaptive behaviors in AUD, such as compulsive alcohol consumption, may require more time to respond to treatment than those involved in glycemic control.</p><p>Our results suggest that GLP&#x02010;RAs may be particularly effective in AUD patients with obesity while showing limited responsiveness in those with normal weight. Although the exact mechanisms remain unclear, GLP&#x02010;1 dysfunction is typically more pronounced in obese individuals than in lean individuals (Anandhakrishnan &#x00026; Korbonits,&#x000a0;<xref rid="acer70041-bib-0002" ref-type="bibr">2016</xref>). GLP&#x02010;1 receptors are present in the ventral tegmental area and nucleus accumbens (Alhadeff et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0001" ref-type="bibr">2012</xref>), which are fundamental brain regions within dopamine reward pathways modulating the rewarding effects of both alcohol and food (Volkow et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0027" ref-type="bibr">2017</xref>). Since heightened reward sensitivity to food can drive overeating and obesity (Volkow et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0026" ref-type="bibr">2013</xref>), this dysfunction may represent a compounded disruption of both the GLP&#x02010;1 and reward systems when obesity and AUD co&#x02010;occur. Additionally, food and sugar cravings can exacerbate alcohol cravings (Braun et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0003" ref-type="bibr">2021</xref>), potentially leading to increased alcohol consumption and greater AUD severity. Importantly, recent research has shown that higher BMI in males predicts an increased risk of AUD relapse (Hoffmann et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0011" ref-type="bibr">2023</xref>), suggesting that obesity may play a significant role in AUD. By regulating appetite and satiety signals, GLP&#x02010;1 activity may help control both food and alcohol intake in patients with obesity, yielding improved outcomes in AUD. Thus, GLP&#x02010;RA treatment may offer a dual benefit in targeting disrupted metabolic and reward pathways, producing a stronger therapeutic response. This dual action could explain why the effects observed here on PEth were evident only in obese AUD patients.</p><p>This study has several limitations. First, there was a considerable dropout rate (around 40%), as is often the case in AUD trials (Hallgren &#x00026; Witkiewitz,&#x000a0;<xref rid="acer70041-bib-0010" ref-type="bibr">2013</xref>), and only 18 out of the 30 participants completed the final week 26 follow&#x02010;up. Consequently, considerable variability in PEth was observed, particularly in the placebo group at Week 26. Another limitation is that the blood samples were initially stored at &#x02212;20&#x000b0;C before being transferred to a &#x02212;80&#x000b0;C freezer, raising the possibility of in&#x000a0;vitro PEth formation in some samples. However, given our handling procedures, this will not likely significantly affect the results. Lastly, a small portion of the samples was collected from participants with a positive breath alcohol concentration (BrAC), though we believe this did not significantly influence the overall findings.</p></sec><sec sec-type="conclusions" id="acer70041-sec-0012"><title>CONCLUSION</title><p>In conclusion, our analysis suggests that exenatide may have a delayed but significant effect on alcohol consumption as measured by PEth in AUD patients with comorbid obesity. These findings warrant further investigation, which is ongoing (NCT05895643) (Klausen et&#x000a0;al.,&#x000a0;<xref rid="acer70041-bib-0014" ref-type="bibr">2025</xref>).</p></sec><sec id="acer70041-sec-0014"><title>FUNDING INFORMATION</title><p>The present study did not receive any funding.</p></sec><sec sec-type="COI-statement" id="acer70041-sec-0015"><title>CONFLICT OF INTEREST STATEMENT</title><p>Tina Vilsb&#x000f8;ll has, over the recent three years, served on scientific advisory panels, been part of speaker's bureaus, and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals. The other authors report no conflicts of interest.</p></sec></body><back><ack id="acer70041-sec-0013"><title>ACKNOWLEDGMENTS</title><p>The authors thank Martin Javors and Judith Hahn for their assistance in interpreting PEth data.</p></ack><sec sec-type="data-availability" id="acer70041-sec-0017"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="acer70041-bibl-0001"><title>REFERENCES</title><ref id="acer70041-bib-0001"><mixed-citation publication-type="journal" id="acer70041-cit-0001">
<string-name>
<surname>Alhadeff</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Rupprecht</surname>, <given-names>L.E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Hayes</surname>, <given-names>M.R.</given-names>
</string-name> (<year>2012</year>) <article-title>GLP&#x02010;1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake</article-title>. <source>Endocrinology</source>, <volume>153</volume>, <fpage>647</fpage>&#x02013;<lpage>658</lpage>.<pub-id pub-id-type="pmid">22128031</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0002"><mixed-citation publication-type="journal" id="acer70041-cit-0002">
<string-name>
<surname>Anandhakrishnan</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Korbonits</surname>, <given-names>M.</given-names>
</string-name> (<year>2016</year>) <article-title>Glucagon&#x02010;like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity</article-title>. <source>World Journal of Diabetes</source>, <volume>7</volume>, <fpage>572</fpage>&#x02013;<lpage>598</lpage>.<pub-id pub-id-type="pmid">28031776</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0003"><mixed-citation publication-type="journal" id="acer70041-cit-0003">
<string-name>
<surname>Braun</surname>, <given-names>T.D.</given-names>
</string-name>, <string-name>
<surname>Kunicki</surname>, <given-names>Z.J.</given-names>
</string-name>, <string-name>
<surname>Blevins</surname>, <given-names>C.E.</given-names>
</string-name>, <string-name>
<surname>Stein</surname>, <given-names>M.D.</given-names>
</string-name>, <string-name>
<surname>Marsh</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Feltus</surname>, <given-names>S.</given-names>
</string-name> et&#x000a0;al. (<year>2021</year>) <article-title>Prospective associations between attitudes toward sweet foods, sugar consumption, and cravings for alcohol and sweets in early recovery from alcohol use disorders</article-title>. <source>Alcoholism Treatment Quarterly</source>, <volume>39</volume>, <fpage>269</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">34566252</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0004"><mixed-citation publication-type="journal" id="acer70041-cit-0004">
<string-name>
<surname>Carvalho</surname>, <given-names>A.F.</given-names>
</string-name>, <string-name>
<surname>Heilig</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Perez</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Probst</surname>, <given-names>C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Rehm</surname>, <given-names>J.</given-names>
</string-name> (<year>2019</year>) <article-title>Alcohol use disorders</article-title>. <source>The Lancet</source>, <volume>394</volume>, <fpage>781</fpage>&#x02013;<lpage>792</lpage>.</mixed-citation></ref><ref id="acer70041-bib-0005"><mixed-citation publication-type="journal" id="acer70041-cit-0005">
<string-name>
<surname>Egecioglu</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Engel</surname>, <given-names>J.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Jerlhag</surname>, <given-names>E.</given-names>
</string-name> (<year>2013</year>) <article-title>The glucagon&#x02010;like peptide 1 analogue, exendin&#x02010;4, attenuates the rewarding properties of psychostimulant drugs in mice</article-title>. <source>PLoS One</source>, <volume>8</volume>, <elocation-id>e69010</elocation-id>.<pub-id pub-id-type="pmid">23874851</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0006"><mixed-citation publication-type="journal" id="acer70041-cit-0006">
<string-name>
<surname>Fineman</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Flanagan</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Aisporna</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Shen</surname>, <given-names>L.Z.</given-names>
</string-name>, <string-name>
<surname>Mace</surname>, <given-names>K.F.</given-names>
</string-name> et&#x000a0;al. (<year>2011</year>) <article-title>Pharmacokinetics and pharmacodynamics of exenatide extended&#x02010;release after single and multiple dosing</article-title>. <source>Clinical Pharmacokinetics</source>, <volume>50</volume>, <fpage>65</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">21142268</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0007"><mixed-citation publication-type="journal" id="acer70041-cit-0007">
<string-name>
<surname>Fink&#x02010;Jensen</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>W&#x000f6;rtwein</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Klausen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name>
<surname>Holst</surname>, <given-names>J.J.</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Thomsen</surname>, <given-names>M.</given-names>
</string-name> et&#x000a0;al. (<year>2024</year>) <article-title>Effect of the glucagon&#x02010;like peptide&#x02010;1 (GLP&#x02010;1) receptor agonist semaglutide on alcohol consumption in alcohol&#x02010;preferring male vervet monkeys</article-title>. <source>Psychopharmacology</source>, <volume>242</volume>, <fpage>63</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">38884652</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0008"><mixed-citation publication-type="journal" id="acer70041-cit-0008">
<string-name>
<surname>Fortin</surname>, <given-names>S.M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Roitman</surname>, <given-names>M.F.</given-names>
</string-name> (<year>2017</year>) <article-title>Central GLP&#x02010;1 receptor activation modulates cocaine&#x02010;evoked phasic dopamine signaling in the nucleus accumbens core</article-title>. <source>Physiology &#x00026; Behavior</source>, <volume>176</volume>, <fpage>17</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">28315693</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0009"><mixed-citation publication-type="journal" id="acer70041-cit-0009">
<string-name>
<surname>Graham</surname>, <given-names>D.L.</given-names>
</string-name>, <string-name>
<surname>Erreger</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Galli</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Stanwood</surname>, <given-names>G.D.</given-names>
</string-name> (<year>2013</year>) <article-title>GLP&#x02010;1 analog attenuates cocaine reward</article-title>. <source>Molecular Psychiatry</source>, <volume>18</volume>, <fpage>961</fpage>&#x02013;<lpage>962</lpage>.<pub-id pub-id-type="pmid">23089631</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0010"><mixed-citation publication-type="journal" id="acer70041-cit-0010">
<string-name>
<surname>Hallgren</surname>, <given-names>K.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Witkiewitz</surname>, <given-names>K.</given-names>
</string-name> (<year>2013</year>) <article-title>Missing data in alcohol clinical trials: a comparison of methods</article-title>. <source>Alcoholism: Clinical and Experimental Research</source>, <volume>37</volume>, <fpage>2152</fpage>&#x02013;<lpage>2160</lpage>.<pub-id pub-id-type="pmid">23889334</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0011"><mixed-citation publication-type="journal" id="acer70041-cit-0011">
<string-name>
<surname>Hoffmann</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gerhardt</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Koopmann</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bach</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Sommer</surname>, <given-names>W.H.</given-names>
</string-name>, <string-name>
<surname>Kiefer</surname>, <given-names>F.</given-names>
</string-name> et&#x000a0;al. (<year>2023</year>) <article-title>Body mass index interacts with sex to predict readmission in in&#x02010;patients with alcohol use disorder</article-title>. <source>Addiction Biology</source>, <volume>28</volume>, <elocation-id>e13239</elocation-id>.<pub-id pub-id-type="pmid">36577723</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0012"><mixed-citation publication-type="journal" id="acer70041-cit-0012">
<string-name>
<surname>Kechagias</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Dernroth</surname>, <given-names>D.N.</given-names>
</string-name>, <string-name>
<surname>Blomgren</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Hansson</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Isaksson</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Walther</surname>, <given-names>L.</given-names>
</string-name> et&#x000a0;al. (<year>2015</year>) <article-title>Phosphatidylethanol compared with other blood tests as a biomarker of moderate alcohol consumption in healthy volunteers: a prospective randomized study</article-title>. <source>Alcohol and Alcoholism</source>, <volume>50</volume>, <fpage>399</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">25882743</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0013"><mixed-citation publication-type="journal" id="acer70041-cit-0013">
<string-name>
<surname>Klausen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>, <given-names>M.E.</given-names>
</string-name>, <string-name>
<surname>M&#x000f8;ller</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>le Dous</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Jensen</surname>, <given-names>A.M.&#x000d8;.</given-names>
</string-name>, <string-name>
<surname>Zeeman</surname>, <given-names>V.A.</given-names>
</string-name> et&#x000a0;al. (<year>2022</year>) <article-title>Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo&#x02010;controlled clinical trial</article-title>. <source>JCI Insight</source>, <volume>7</volume>, <elocation-id>e159863</elocation-id>.<pub-id pub-id-type="pmid">36066977</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0014"><mixed-citation publication-type="journal" id="acer70041-cit-0014">
<string-name>
<surname>Klausen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name>
<surname>Kuzey</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Pedersen</surname>, <given-names>J.N.</given-names>
</string-name>, <string-name>
<surname>Justesen</surname>, <given-names>S.K.</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Knorr</surname>, <given-names>U.B.</given-names>
</string-name> et&#x000a0;al. (<year>2025</year>) <article-title>Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double&#x02010;blinded, placebo&#x02010;controlled clinical trial (the SEMALCO trial)</article-title>. <source>BMJ Open</source>, <volume>15</volume>, <elocation-id>e086454</elocation-id>.</mixed-citation></ref><ref id="acer70041-bib-0015"><mixed-citation publication-type="journal" id="acer70041-cit-0015">
<string-name>
<surname>Kranzler</surname>, <given-names>H.R.</given-names>
</string-name> &#x00026; <string-name>
<surname>Soyka</surname>, <given-names>M.</given-names>
</string-name> (<year>2018</year>) <article-title>Diagnosis and pharmacotherapy of alcohol use disorder: a review</article-title>. <source>JAMA</source>, <volume>320</volume>, <fpage>815</fpage>&#x02013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">30167705</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0016"><mixed-citation publication-type="journal" id="acer70041-cit-0016">
<string-name>
<surname>Leggio</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Hendershot</surname>, <given-names>C.S.</given-names>
</string-name>, <string-name>
<surname>Farokhnia</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Fink&#x02010;Jensen</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Klausen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name>
<surname>Schacht</surname>, <given-names>J.P.</given-names>
</string-name> et&#x000a0;al. (<year>2023</year>) <article-title>GLP&#x02010;1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders</article-title>. <source>Nature Medicine</source>, <volume>29</volume>, <fpage>2993</fpage>&#x02013;<lpage>2995</lpage>.</mixed-citation></ref><ref id="acer70041-bib-0017"><mixed-citation publication-type="journal" id="acer70041-cit-0017">
<string-name>
<surname>Luginbuhl</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Wurst</surname>, <given-names>F.M.</given-names>
</string-name>, <string-name>
<surname>St&#x000f6;th</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Weinmann</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Stove</surname>, <given-names>C.P.</given-names>
</string-name> &#x00026; <string-name>
<surname>Van Uytfanghe</surname>, <given-names>K.</given-names>
</string-name> (<year>2022</year>) <article-title>Consensus for the use of the alcohol biomarker phosphatidylethanol (PEth) for the assessment of abstinence and alcohol consumption in clinical and forensic practice (2022 consensus of Basel)</article-title>. <source>Drug Testing and Analysis</source>, <volume>14</volume>, <fpage>1800</fpage>&#x02013;<lpage>1802</lpage>.<pub-id pub-id-type="pmid">35851997</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0018"><mixed-citation publication-type="journal" id="acer70041-cit-0018">
<string-name>
<surname>Quddos</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Hubshman</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Tegge</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Sane</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Marti</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Kablinger</surname>, <given-names>A.S.</given-names>
</string-name> et&#x000a0;al. (<year>2023</year>) <article-title>Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity</article-title>. <source>Scientific Reports</source>, <volume>13</volume>, <fpage>20998</fpage>.<pub-id pub-id-type="pmid">38017205</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0019"><mixed-citation publication-type="journal" id="acer70041-cit-0019">
<string-name>
<surname>Reddy</surname>, <given-names>I.A.</given-names>
</string-name>, <string-name>
<surname>Pino</surname>, <given-names>J.A.</given-names>
</string-name>, <string-name>
<surname>Weikop</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Osses</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>S&#x000f8;rensen</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Bering</surname>, <given-names>T.</given-names>
</string-name> et&#x000a0;al. (<year>2016</year>) <article-title>Glucagon&#x02010;like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels</article-title>. <source>Translational Psychiatry</source>, <volume>6</volume>, <elocation-id>e809</elocation-id>.<pub-id pub-id-type="pmid">27187231</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0020"><mixed-citation publication-type="journal" id="acer70041-cit-0020">
<string-name>
<surname>Richards</surname>, <given-names>J.R.</given-names>
</string-name>, <string-name>
<surname>Dorand</surname>, <given-names>M.F.</given-names>
</string-name> &#x00026; <string-name>
<surname>Royal</surname>, <given-names>K.</given-names>
</string-name> (<year>2023</year>) <article-title>Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series</article-title>. <source>The Journal of Clinical Psychiatry</source>, <volume>85</volume>, <elocation-id>23m15068</elocation-id>.</mixed-citation></ref><ref id="acer70041-bib-0021"><mixed-citation publication-type="journal" id="acer70041-cit-0021">
<string-name>
<surname>Richards</surname>, <given-names>V.L.</given-names>
</string-name>, <string-name>
<surname>Sajdeya</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Villalba</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Brumback</surname>, <given-names>B.</given-names>
</string-name> et&#x000a0;al. (<year>2021</year>) <article-title>Secondary analysis of a randomized clinical trial of naltrexone among women living with HIV: correlations between reductions in self&#x02010;reported alcohol use and changes in Phosphatidylethanol</article-title>. <source>Alcoholism: Clinical and Experimental Research</source>, <volume>45</volume>, <fpage>174</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">33190242</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0022"><mixed-citation publication-type="journal" id="acer70041-cit-0022">
<string-name>
<surname>S&#x000f8;rensen</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>, <given-names>I.A.</given-names>
</string-name>, <string-name>
<surname>Weikop</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Graham</surname>, <given-names>D.L.</given-names>
</string-name>, <string-name>
<surname>Stanwood</surname>, <given-names>G.D.</given-names>
</string-name>, <string-name>
<surname>Wortwein</surname>, <given-names>G.</given-names>
</string-name> et&#x000a0;al. (<year>2015</year>) <article-title>The glucagon&#x02010;like peptide 1 (GLP&#x02010;1) receptor agonist exendin&#x02010;4 reduces cocaine self&#x02010;administration in mice</article-title>. <source>Physiology &#x00026; Behavior</source>, <volume>149</volume>, <fpage>262</fpage>&#x02013;<lpage>268</lpage>.<pub-id pub-id-type="pmid">26072178</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0023"><mixed-citation publication-type="journal" id="acer70041-cit-0023">
<string-name>
<surname>Thomsen</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dencker</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>W&#x000f6;rtwein</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Weikop</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Egecioglu</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Jerlhag</surname>, <given-names>E.</given-names>
</string-name> et&#x000a0;al. (<year>2017</year>) <article-title>The glucagon&#x02010;like peptide 1 receptor agonist Exendin&#x02010;4 decreases relapse&#x02010;like drinking in socially housed mice</article-title>. <source>Pharmacology, Biochemistry, and Behavior</source>, <volume>160</volume>, <fpage>14</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">28778739</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0024"><mixed-citation publication-type="journal" id="acer70041-cit-0024">
<string-name>
<surname>Tuesta</surname>, <given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Duncan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Fowler</surname>, <given-names>C.D.</given-names>
</string-name>, <string-name>
<surname>Ishikawa</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>B.R.</given-names>
</string-name> et&#x000a0;al. (<year>2017</year>) <article-title>GLP&#x02010;1 acts on habenular avoidance circuits to control nicotine intake</article-title>. <source>Nature Neuroscience</source>, <volume>20</volume>, <fpage>708</fpage>&#x02013;<lpage>716</lpage>.<pub-id pub-id-type="pmid">28368384</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0025"><mixed-citation publication-type="journal" id="acer70041-cit-0025">
<string-name>
<surname>Volkow</surname>, <given-names>N.D.</given-names>
</string-name>, <string-name>
<surname>Koob</surname>, <given-names>G.F.</given-names>
</string-name> &#x00026; <string-name>
<surname>McLellan</surname>, <given-names>A.T.</given-names>
</string-name> (<year>2016</year>) <article-title>Neurobiologic advances from the brain disease model of addiction</article-title>. <source>New England Journal of Medicine</source>, <volume>374</volume>, <fpage>363</fpage>&#x02013;<lpage>371</lpage>.<pub-id pub-id-type="pmid">26816013</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0026"><mixed-citation publication-type="journal" id="acer70041-cit-0026">
<string-name>
<surname>Volkow</surname>, <given-names>N.D.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>G.J.</given-names>
</string-name>, <string-name>
<surname>Tomasi</surname>, <given-names>D.</given-names>
</string-name> &#x00026; <string-name>
<surname>Baler</surname>, <given-names>R.D.</given-names>
</string-name> (<year>2013</year>) <article-title>The addictive dimensionality of obesity</article-title>. <source>Biological Psychiatry</source>, <volume>73</volume>, <fpage>811</fpage>&#x02013;<lpage>818</lpage>.<pub-id pub-id-type="pmid">23374642</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0027"><mixed-citation publication-type="journal" id="acer70041-cit-0027">
<string-name>
<surname>Volkow</surname>, <given-names>N.D.</given-names>
</string-name>, <string-name>
<surname>Wise</surname>, <given-names>R.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Baler</surname>, <given-names>R.</given-names>
</string-name> (<year>2017</year>) <article-title>The dopamine motive system: implications for drug and food addiction</article-title>. <source>Nature Reviews Neuroscience</source>, <volume>18</volume>, <fpage>741</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">29142296</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0028"><mixed-citation publication-type="journal" id="acer70041-cit-0028">
<string-name>
<surname>Walther</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>de Bejczy</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>L&#x000f6;f</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Hansson</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Andersson</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Guterstam</surname>, <given-names>J.</given-names>
</string-name> et&#x000a0;al. (<year>2015</year>) <article-title>Phosphatidylethanol is superior to carbohydrate&#x02010;deficient transferrin and &#x003b3;&#x02010;glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level</article-title>. <source>Alcoholism, Clinical and Experimental Research</source>, <volume>39</volume>, <fpage>2200</fpage>&#x02013;<lpage>2208</lpage>.<pub-id pub-id-type="pmid">26503066</pub-id>
</mixed-citation></ref><ref id="acer70041-bib-0029"><mixed-citation publication-type="journal" id="acer70041-cit-0029">
<string-name>
<surname>Wang</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Volkow</surname>, <given-names>N.D.</given-names>
</string-name>, <string-name>
<surname>Berger</surname>, <given-names>N.A.</given-names>
</string-name>, <string-name>
<surname>Davis</surname>, <given-names>P.B.</given-names>
</string-name>, <string-name>
<surname>Kaelber</surname>, <given-names>D.C.</given-names>
</string-name> &#x00026; <string-name>
<surname>Xu</surname>, <given-names>R.</given-names>
</string-name> (<year>2024</year>) <article-title>Associations of semaglutide with incidence and recurrence of alcohol use disorder in real&#x02010;world population</article-title>. <source>Nature Communications</source>, <volume>15</volume>, <fpage>4548</fpage>.</mixed-citation></ref><ref id="acer70041-bib-0030"><mixed-citation publication-type="journal" id="acer70041-cit-0030">
<string-name>
<surname>Wium&#x02010;Andersen</surname>, <given-names>I.K.</given-names>
</string-name>, <string-name>
<surname>Wium&#x02010;Andersen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name>
<surname>Fink&#x02010;Jensen</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Rungby</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>J&#x000f8;rgensen</surname>, <given-names>M.B.</given-names>
</string-name> &#x00026; <string-name>
<surname>Osler</surname>, <given-names>M.</given-names>
</string-name> (<year>2022</year>) <article-title>Use of GLP&#x02010;1 receptor agonists and subsequent risk of alcohol&#x02010;related events. A nationwide register&#x02010;based cohort and self&#x02010;controlled case series study</article-title>. <source>Basic &#x00026; Clinical Pharmacology &#x00026; Toxicology</source>, <volume>131</volume>, <fpage>372</fpage>&#x02013;<lpage>379</lpage>.<pub-id pub-id-type="pmid">35968738</pub-id>
</mixed-citation></ref></ref-list></back></article>